Unusually prolonged pemetrexed cytotoxicity in a patient with a lung adenocarcinoma: a case report

نویسندگان

  • Linda Sakhri
  • Julian Pinsolle
  • Denis Moro-Sibilot
  • Hélène Pluchart
چکیده

BACKGROUND We describe a case of pemetrexed toxicities related to reabsorption by an ileal neobladder, which caused prolonged hematotoxicity and nephrotoxicity. CASE PRESENTATION A 59-year-old white man was diagnosed with metastatic wild-type adenocarcinoma of the upper lobe of his right lung. After a first cycle of cisplatin and pemetrexed, he had unusually prolonged aplasia and acute kidney injury. The prolonged aplasia was caused by pemetrexed reabsorption by the ileal mucosa of the neobladder as pemetrexed was eliminated renally in an active form and is partly lipophilic. CONCLUSIONS Pemetrexed may be reabsorbed by the ileal mucosa of the neobladder because of its hydrophobic structure and renal excretion in its active form. Acute urinary retention may maintain this phenomenon. Published data excluded a potential role for cisplatin in this toxicity; furthermore, we could not assess pemetrexed concentrations in the blood or urine as these assay techniques are not validated. Thus, care is needed when giving chemotherapy to patients with a neobladder.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Metastasis of Lung Adenocarcinoma to the Gingiva: A Rare Case Report

Metastatic tumors account for 1% of all oral malignancies. Metastasis to jaw bones is common, particularly in the mandible, rare in the oral soft tissues, and account for only 0.1% of oral malignancies. The majority of metastatic cases (70%) reported in the literature have primary tumors located in the lung, breast, kidney, and colon. Metastasis is a biological complex process that involves det...

متن کامل

Long-term progression-free survival in an advanced lung adenocarcinoma patient harboring EZR-ROS1 rearrangement: a case report

BACKGROUND Crizotinib is recommended as first-line therapy in ROS1-driven lung adenocarcinoma. However, the optimal first-line therapy for this subgroup of lung cancer is controversial according to the available clinical data. CASE PRESENTATION Here, we describe a 57-year-old man who was diagnosed with stage IIIB lung adenocarcinoma and EGFR/KRAS/ALK-negative tumors. The patient received six ...

متن کامل

A Case Report of Small Cell Lung Carcinoma in a Patient with Progressive Diffuse Sclerosis

 Connective tissue diseases, including scleroderma, may be associated with an increased risk of lung cancer. The most common type of lung cancer associated with systemic sclerosis is adenocarcinoma or bronchoalveolar carcinoma, and small cell carcinoma is rare. This reports presents a 54-year-old non-smoker woman with a history of scleroderma who was examined due to aggravation of shortness of ...

متن کامل

Prolonged Hemoptysis Caused by Primary Pulmonary Epithelioid Hemangioendothelioma; A Case Report and Review of the Literature

Epithelioid hemangioendothelioma is a vascular tumor with an intermediate malignant potential. This tumor is very rare in the lung parenchyma, and most of the previously reported cases have been asymptomatic. There is no standard therapy for this tumor and prognosis in the previous reports has been variable.Herein we report our experience with a 60-year-old woman presenting with hemoptysis and ...

متن کامل

Pemetrexed and cisplatin followed sequentially by gefitinib as neo-adjuvant therapy for stage IIB EGFR-mutation-positive lung adenocarcinoma patient: a case report and literature review

Early-stage non-small-cell lung cancer (NSCLC) patients with EGFR mutation positive have a poor prognosis even after complete resection, which raised growing demands for multimodal therapies. Sequential therapy with chemotherapy and EGFR-TKI for advanced EGFR mutation-positive NSCLC patients significantly prolonged PFS, but there has been no report of the efficacy and complications of it in neo...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:

دوره 11  شماره 

صفحات  -

تاریخ انتشار 2017